Welcome to our dedicated page for Restart Life news (Ticker: NMLSF), a resource for investors and traders seeking the latest updates and insights on Restart Life stock.
Restart Life (NMLSF) is a biotechnology innovator advancing psilocybin-based therapies for neuroinflammatory disorders through clinical research and strategic intellectual property management. This page provides investors and researchers with verified updates on the company’s clinical trials, technology licensing agreements, and therapeutic development milestones.
Access real-time announcements about Restart Life’s proprietary mRNA assay platforms, fragile X syndrome research, and partnership-driven revenue models. Key updates include progress reports on neuroinflammation studies, intellectual property conveyance agreements, and regulatory compliance achievements.
All content undergoes strict editorial review to ensure accuracy and relevance for financial analysis. Bookmark this page for centralized access to Restart Life’s press releases, earnings disclosures, and material event notifications within the competitive biotech landscape.
Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.
NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.
Wellbeing Digital Sciences Inc. (OTC: KONEF) announces the recruitment of participants for a pioneering clinical trial examining the effects of psilocybin on adults with fragile X syndrome (FXS). Conducted by its subsidiary KGK Sciences, the 28-day Phase IIA study is the first authorized by Health Canada allowing take-home psilocybin dosing. The study, set to treat its first participant in Q2 2023, aims to evaluate the safety and efficacy of Nova Mentis’ psilocybin drug (NM-1001) in a controlled environment, using advanced diagnostic technologies. Preliminary results are expected later this year, highlighting significant potential for psilocybin therapy in addressing unmet medical needs related to FXS.
Wellbeing Digital Sciences Inc. (KONEF, NMLSF) has announced that its subsidiary, KGK Sciences Inc., gained IRB approval in Canada to conduct a groundbreaking Phase IIA clinical trial. This study will test the efficacy of psilocybin on adults with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD). The trial is part of a partnership with Nova Mentis Life Science Corp., aiming to assess psilocybin's impact on cognitive and behavioral symptoms. Patient recruitment is expected to begin this year. Notably, Health Canada has granted special permission for participants to take the drug home, marking a significant milestone in clinical research. This trial supports Nova's ongoing efforts to improve treatment options for FXS patients, following their FDA Orphan Drug designation received in 2021.
Wellbeing Digital Sciences Inc. (KONEF, NMLSF) announces its subsidiary, KGK Sciences, has received a Section 56 exemption to proceed with a Phase IIA clinical trial evaluating microdose psilocybin therapy for fragile X syndrome (FXS). This trial aims to study cognitive and behavioral symptoms linked to FXS, a major genetic cause of autism spectrum disorder. The study is significant as it represents a pioneering approach in this area, supported by a No Objection Letter from Health Canada. With the production of cGMP synthetic psilocybin underway, the trial seeks to enhance understanding of psilocybin's therapeutic potential, with participant recruitment starting in early 2023.
Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences has received approval from
Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences submitted a clinical trial application for a Phase IIa study testing the efficacy of psilocybin in treating cognitive and behavioral symptoms associated with Fragile X Syndrome (FXS). The trial, sponsored by Nova Mentis Life Science Corp., will assess a 1.5 mg microdose of psilocybin and is expected to begin in early 2023 pending Health Canada's approval. This study marks a significant milestone as the first human trial using psilocybin for FXS.
Wellbeing Digital Sciences (OTC: KONEF, NEO: MEDI) announced that its subsidiary KGK Science will conduct a Phase II clinical trial to evaluate the effects of psilocybin on Fragile X syndrome. This marks the first research into psilocybin microdoses for improving behavioral and cognitive symptoms associated with the disorder. The trial, which will involve 10 participants, supports Nova Mentis’ drug development efforts under FDA Orphan Drug designation. Results are aimed at addressing significant unmet medical needs in treatment.
